INDICAID COVID-19 Rapid Antigen Test – Instructions for Use
Unique
As the COVID-19 pandemic advances, there is a rising requirement for fast, open examines for SARS-CoV-2 location. We present a clinical assessment and genuine execution of the INDICAID COVID-19 quick antigen test (INDICAID fast test). A multisite clinical assessment of the INDICAID quick test utilizing tentatively gathered nasal (two-sided foremost) swab tests from suggestive subjects was performed.
The INDICAID quick test exhibited a positive percent understanding (PPA) and negative percent arrangement (NPA) of 85.3% (95% certainty span [95% CI], 75.6% to 91.6%) and 94.9% (95% CI, 91.6% to 96.9%), individually, contrasted with research center based switch transcriptase PCR (RT-PCR) utilizing nasal examples.
The INDICAID fast test was then carried out at COVID-19 flare-up screening habitats in Hong Kong as a feature of a testing calculation (named “double track”) to evaluate asymptomatic people for prioritization for corroborative RT-PCR testing. In one methodology, fundamental positive INDICAID fast experimental outcomes set off assisted handling for research center based RT-PCR, lessening the typical chance to corroborative outcome from 10.85 h to 7.0 h.
In a subsequent methodology, starter positive outcomes set off ensuing testing with an on location fast RT-PCR, decreasing the normal chance to corroborative outcome to 0.84 h. In 22,994 asymptomatic patients, the INDICAID fast test exhibited a PPA of 84.2% (95% CI, 69.6% to 92.6%) and a NPA of 99.9% (95% CI, 99.9% to 100 percent)
- contrasted with lab based RT-PCR utilizing consolidated nasal/oropharyngeal examples.
- The INDICAID quick test has astounding execution contrasted with research center based RT-PCR testing and, when utilized pair with RT-PCR, decreases the opportunity to corroborative positive outcome.
Significance Laboratory-based RT-PCR, the ongoing highest quality level for COVID-19 testing, can require a completion time of 24 to 48 h from test assortment to result. The postponed opportunity as far as possible the adequacy of concentrated RT-PCR testing to diminish transmission and stem expected flare-ups. To address this, we directed a careful assessment of the INDICAID COVID-19 quick antigen test, a 20-minute fast antigen test, in both suggestive and asymptomatic populaces.
The INDICAID quick test showed high awareness and explicitness with RT-PCR as the comparator technique. A double track testing calculation was additionally assessed using the INDICAID quick test to evaluate for fundamental positive patients, whose examples were then focused on for RT-PCR testing. The double track technique showed huge upgrades in assisting the announcing of positive RT-PCR test results contrasted with standard RT-PCR testing without prioritization, offering a superior methodology for local area testing and controlling SARS-CoV-2 episodes.
Deals and transportation just accessible in Hong Kong.
INDICAID COVID-19 Rapid Antigen Test (FDA EUA, CE) is a sidelong stream immunoassay intended for the subjective location of SARS-CoV-2 antigens in direct nasal swab tests. Find out additional.
Item Benefits
Quick: Intuitive visual outcomes shortly
Exact : Clinically approved with generally awareness and explicitness at 96% and 99.9% individually
Simple to-Use: No exceptional hardware or offices required
Created in Hong Kong: With solid item quality
Item Certification: The primary COVID-19 item in Greater China that has acquired US FDA EUA and EU CE mark
Variations perceptibility: Able to distinguish the presence of specific COVID-19 variants*
*Discernible variations incorporate Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Delta Plus (AY.1 and AY.2), and Omicron (B.1.1.529)
SARS-CoV-2 Antigen Rapid Test Kit | ||||
| CoV2Ag-1 | UnScience | 1T | 9.6 EUR | |
SARS-CoV-2 Antigen Rapid Test Kit | ||||
| CoV2Ag-25 | UnScience | 25T/kit | 42 EUR | |
NOVATest Antigen Rapid Test Kit (For Single Use) (NOVA Test) | ||||
| nCov-500-01 | Atlas Link Technology | 1T | 162 EUR | |
NOVATest Antigen Rapid Kit (NOVA Test) | ||||
| nCov-500 | Atlas Link Technology | 20 Tests | 162 EUR | |
SARS-CoV-2 Rapid Antigen Test Nasal | ||||
| 9901-NCOV-03G | Roche Diagnostics | 25 Tests/Kit | 112.8 EUR | |
Human Streptococcus Pneumoniae (SP) Antigen Rapid Test Kit | ||||
| abx092096-20tests | Abbexa | 20 tests | 477.6 EUR | |
Avian Influenza Virus Antigen Rapid Test Kit (Colloidal gold) | ||||
| abx092015-40tests | Abbexa | 40 tests | 518.4 EUR | |
Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) | ||||
| IOV87952 | INVBIO | 20T/kit | 46.8 EUR | |
Newcastle Disease Virus Antigen Rapid Test Kit (Colloidal gold) | ||||
| abx092016-40tests | Abbexa | 40 tests | 518.4 EUR | |
Human Chlamydia Trachomatis Antigen Rapid Test Kit (Colloidal gold) | ||||
| abx092049-20tests | Abbexa | 20 tests | 276 EUR | |
Avian Influenza H5 Virus Antigen Rapid Test Kit (Colloidal gold) | ||||
| abx092014-40tests | Abbexa | 40 tests | 585.6 EUR | |
Avian Influenza H7 Virus Antigen Rapid Test Kit (Colloidal gold) | ||||
| abx092017-40tests | Abbexa | 40 tests | 518.4 EUR | |
Accu-Tell COVID-19 IgG/IgM Rapid Test | ||||
| GEN-B352-20tests | Accu test | 20 tests | 283.2 EUR | |
Accu-Tell COVID-19 IgG/IgM Rapid Test | ||||
| GEN-B352-40tests | Accu test | 40 tests | 385.2 EUR | |
TruStrip RDT Anthrax Protective antigen 83 (PA83) Rapid Test cards, 25/pk | ||||
| 800-100-RDT-25 | Alpha Diagnostics | 1 pk | 489.6 EUR | |
2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) | ||||
| GEN-402-25tests | All test | 25 tests | 292.8 EUR | |
Guidance
Gather nasal swab test
Blend test into the cradle arrangement
Add the cradle arrangement into the example well
Peruse the outcome following 20 minutes and something like 25 minutes